全球领先疫苗,39支疫苗进入3期实验,10月13日,德国法国放弃两款mRNA疫苗,转为研发新一代疫苗和加强剂。中国两款疫苗进入第三期试验。

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373
12岁以上
7 hr 14 min ago

Pfizer/BioNTech vaccine is 100% effective in 12-15 year olds, clinical trial results show​

From CNN Health’s Lauren Mascarenhas

Clinical trial results of Pfizer/BioNTech's Covid-19 vaccine showed its efficacy is 100% and it is well tolerated in youths ages 12 to 15, the companies said Wednesday.

Pfizer/BioNTech plan to submit the data to the US Food and Drug Administration as soon as possible for expanded emergency use authorization of the two-dose vaccine.

In a Phase 3 trial of 2,260 participants ages 12 to 15 years in the US, the vaccine elicited strong antibody responses one month after the second dose, exceeding those demonstrated in people ages 16 to 25 in previous trials, Pfizer/BioNTech reported. The vaccine is currently authorized in the US for emergency use in people ages 16 and older.

Researchers observed 18 Covid-19 cases among the 1,129 participants who were given a placebo, and none among the 1,131 participants who were given the vaccine. The data has yet to be peer reviewed.

Pfizer/BioNTech added that the side effects observed in people ages 12 to 15 were similar to those seen in 16 to 25-year-olds. The participants will be monitored for protection and safety for two years after their second dose.

“We share the urgency to expand the authorization of our vaccine to use in younger populations and are encouraged by the clinical trial data from adolescents between the ages of 12 and 15,” said Pfizer CEO Albert Bourla.

"We plan to submit these data to FDA as a proposed amendment to our Emergency Use Authorization in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year.”

A separate Phase 1/2/3 study of the Pfizer/BioNTech vaccine in children ages 6 months to 11 years launched last week, when the first participants ages 5 to 11 received a shot.

Pfizer/BioNTech plans to begin dosing 2 to 5-year-olds next week and work its way down to participants ages 6 months to 2 years. The company aims to enroll 4,644 children in the trial and expects results by the end of 2021.

Moderna is also testing its Covid-19 vaccine in adolescents and children, in two clinical trials of children ages 12 to 17 and those ages 6 months to 11 years.
Read more here:
Pfizer/BioNTech says its Covid-19 vaccine is 100% effective and well tolerated in adolescents
RELATED

Pfizer/BioNTech says its Covid-19 vaccine is 100% effective and well tolerated in adolescents

 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373
4 hr 47 min ago

Pfizer says Covid-19 vaccine works against variants, and protection lasts at least six months​

From CNN's Maggie Fox

Vials of the Pfizer/BioNTech Covid-19 vaccine in Manning, South Carolina, on March 12.
Vials of the Pfizer/BioNTech Covid-19 vaccine in Manning, South Carolina, on March 12. Micah Green/Bloomberg/Getty Images

The ongoing Phase 3 clinical trial of Pfizer/BioNTech's coronavirus vaccine confirms its protection lasts at least six months after the second dose, the companies said Thursday.

It also appears to be fully effective against the worrying B.1.351 variant of the virus, which is the dominant strain circulating in South Africa and which researchers feared had evolved to evade the protection of vaccines, the companies said.

The results are the first look at how long protection for a coronavirus vaccine lasts, and while six months is a modest target, it's longer than the 90 days of protection that had been the best estimate offered to date.

The vaccine remains more than 91% effective against disease with any symptoms for six months, the companies said.

"The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA)," Pfizer and BioNTech said in a joint statement.

On Wednesday, the companies said a small trial of volunteers aged 12 to 15 showed 100% efficacy in that age group.
Read the full story here:

Pfizer says Covid-19 vaccine protection lasts at least six months, protects against variants
RELATED

Pfizer says Covid-19 vaccine protection lasts at least six months, protects against variants

 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373

国产四种疫苗有效率从50%到79%​


来源: heisse 于 2021-04-06 21:47:05

Each of the following vaccines has received use authorization in at least one country.

Name Manufacturer Type of vaccine Efficacy rate
BNT162b2Pfizer-BioNTechmRNA95%
mRNA-1273ModernamRNA94.5%
Ad26.COV2.SJanssen (Johnson & Johnson)Viral vector66%
AZD1222Oxford-AstraZenecaViral vector81.3%Trusted Source
Covishield*Serum Institute of IndiaViral vector81.3%
Ad5-nCovCanSinoViral vector65.28%
Sputnik VGamaleyaViral vector91.6%Trusted Source
CovaxinBharat BiotechInactivated80.6%
BBIBP-CorVSinopharm (Beijing)Inactivated79.34%Trusted Source
Inactivated (Vero Cell)Sinopharm (Wuhan)Inactivated72.51%
CoronaVacSinovacInactivated50.38%
RBD-dimerAnhui Zhifei LongcomProtein subunitUnknown
EpiVacCoronaFBRIProtein subunitUnknown

* Covishield is the Oxford-AstraZeneca vaccine produced for India.

 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373
3 min ago

Third vaccine dose likely needed within 6 to 12 months, Pfizer CEO says​

From CNN's Naomi Thomas and Amanda Sealy

Albert Bourla, chief executive officer of Pfizer pharmaceutical company, is seen at the New York Stock Exchange on January 17, 2019, in New York City.
Albert Bourla, chief executive officer of Pfizer pharmaceutical company, is seen at the New York Stock Exchange on January 17, 2019, in New York City. Drew Angerer/Getty Images

People are likely to need a booster dose of vaccine six to 12 months after their first round, Albert Bourla, CEO of Pfizer, said.

Real-world data shows the Pfizer vaccine is effective against a worrying variant of coronavirus first seen in South Africa, called B.1.351, Bourla said during a CVS Health Live event posted to Facebook Thursday. “Protection goes down by time but still in six months it’s still extremely, extremely high,” he said.

“If you ask me, I think that there will be a need, based on these data, for revaccinations,” Bourla added.

Bourla said it remains to be seen how often this would have to happen, but “a likely scenario is that there will be likely a need for a third dose somewhere between six and 12 months and then from there, there will be an annual re-vaccination. But all this needs to be confirmed.”

“In pandemics, you are as protected as your neighbor,” Bourla said. He said that’s why it’s important that all countries get their citizens vaccinated.
 

向问天

日月神教光明左使
VIP
注册
2012-09-04
消息
60,335
荣誉分数
10,978
声望点数
1,273
3 min ago

Third vaccine dose likely needed within 6 to 12 months, Pfizer CEO says​

From CNN's Naomi Thomas and Amanda Sealy

Albert Bourla, chief executive officer of Pfizer pharmaceutical company, is seen at the New York Stock Exchange on January 17, 2019, in New York City.
Albert Bourla, chief executive officer of Pfizer pharmaceutical company, is seen at the New York Stock Exchange on January 17, 2019, in New York City. Drew Angerer/Getty Images

People are likely to need a booster dose of vaccine six to 12 months after their first round, Albert Bourla, CEO of Pfizer, said.

Real-world data shows the Pfizer vaccine is effective against a worrying variant of coronavirus first seen in South Africa, called B.1.351, Bourla said during a CVS Health Live event posted to Facebook Thursday. “Protection goes down by time but still in six months it’s still extremely, extremely high,” he said.



Bourla said it remains to be seen how often this would have to happen, but “a likely scenario is that there will be likely a need for a third dose somewhere between six and 12 months and then from there, there will be an annual re-vaccination. But all this needs to be confirmed.”

“In pandemics, you are as protected as your neighbor,” Bourla said. He said that’s why it’s important that all countries get their citizens vaccinated.


果然要打3针、4针了。

我们还一针都没有。哎
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373
1619292984378.png

New additions and recent updates
April 23The European Commission is preparing a legal case against AstraZeneca for failing to deliver enough doses.
April 23 法国Valneva灭活疫苗进入第3期试验法国Valneva灭活疫苗进入第3期试验France’s Valneva moves to Phase 3.
April 20 伊朗Shafa Pharmed Pars的灭活疫苗进入第3期试验伊朗Shafa Pharmed Pars的灭活疫苗进入第3期试验Iran’s Shafa Pharmed Pars moves to Phase 3.
April 21 中国的深圳康泰进入第三期试验(搞不懂是灭活还是腺病体疫苗)中国的深圳康泰进入第三期试验(搞不懂是灭活还是腺病体疫苗)China’s Shenzhen Kangtai moves to Phase 3.
April 20Iran’s Razi Vaccine and Serum Research Institute moves to Phase 2.
April 20E.U. regulators say Johnson & Johnson’s vaccine should carry a warning for possible rare blood clots.
April 16Pfizer says people may need an additional shot of the vaccine within a year.
April 15Denmark stops use of the AstraZeneca vaccine.
April 14The European Commission may not renew its vaccine contracts with AstraZeneca and Johnson & Johnson.
April 13U.S. health agencies call for a pause in Johnson & Johnson vaccinations.
April 12Cuba’s Soberana Plus begins Phase 2.
April 12Massachusetts-based Akston Biosciences enters Phase 1/2.
April 9Turkey’s Koçak Farma begins Phase 1.
April 5The Walter Reed Army Institute of Research enters Phase 1.
April 5Japan’s KM Biologics begins Phase 1/2.
April 2France’s OSE Immunotherapeutics enters Phase 1.


PHASE 3
1619293294416.png
1619293321819.png


The French vaccine maker Valneva created a vaccine from chemically inactivated coronaviruses, using an adjuvant from Dynavax. The vaccine, called VLA2001, is currently the only inactivated-virus vaccine being developed in Europe. On Dec. 16, Valneva launched a Phase 1/2 trial in the United Kingdom, and in April the company announced that the trial had delivered positive results. On April 22, Valneva launched a Phase 3 trial on 4,000 volunteers in the United Kingdom. The trial was different from the first wave of studies on Covid-19 vaccines, in which some volunteers got a vaccine and the others received a placebo. With a growing number of vaccines now authorized for use in Britain, such randomized clinical trials are now longer ethical. Instead, Valneva will give VLA2001 to half the volunteers, while the others will receive Vaxzevria, the vaccine made by AstraZeneca. Researchers will then observe whether VLA2001 produces similar levels of antibodies to Vaxzevria.

The company hopes to submit VLA2001 for authorization in fall 2021. The British government has already reached an agreement to purchase 100 million doses of the vaccine should it prove safe and effective, with an option to acquire a further 90 million.
Updated April 23

PHASE 3
1619293364333.png


Shafa Pharmed Pars, an Iranian pharmaceutical company, developed a vaccine made of inactivated coronaviruses. Known as COVIran Barekat, it entered a Phase 1 trial at the end of December. COVIran Barekat is the first vaccine developed in Iran to go into clinical testing. On April 21, the Tehran Times announced that COVIran Barekat has begun Phase 3 trials.
Updated April 21

PHASE 3
1619293258747.png


Shenzhen Kangtai Biological Products is a Chinese company that makes vaccines for diseases such as hepatitis B and measles. In August, AstraZeneca reached an agreement with Shenzhen to supply China with their adenovirus vaccine, despite the reports of corruption and scandals that have the company. In October Shenzhen Kangtai launched a Phase 1 trial on 180 volunteers of its own vaccine, based on inactivated coronaviruses. In February they added a Phase 2 trial to a U.S. registry, where they indicated the trial included 1,000 people and that the study would be completed by the end of the month. The company later registered a Phase 3 trial to begin May 2021.
Updated April 21

深圳康泰生物制品有限公司,以开发,研制乙型肝炎,麻疹等疾病疫苗。去年8月阿斯利康与深圳康泰公司达成协议,向中国提供腺病体疫苗。去年10月,康泰开始灭活疫苗试验,4月21日开始进行第3期试验。
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373
1619653491934.png


New additions and recent updates
April 28A third vaccine from China’s Sinopharm enters Phase 1/2.
April 28 哈萨克斯坦批准使用QazVac 疫苗,将在7月完成疫苗的三期试验。Kazakhstan begins public use of its QazVac vaccine.
April 26 德州儿童医院在2002年SARS之后开始研发的疫苗,后来因资金断供而停止,因为新冠病毒与非典有很多的相似性,去年恢复疫苗研发,11月开始1、2期试验,4月26日开始进入三期试验。A vaccine from Baylor College of Medicine and Texas Children’s Hospital moves to Phase 3.

April 23The European Commission is preparing a legal case against AstraZeneca for failing to deliver enough doses.
April 23 法国Valneva灭活疫苗进入第3期试验France’s Valneva moves to Phase 3.
April 20 伊朗Shafa Pharmed Pars的灭活疫苗进入第3期试验Iran’s Shafa Pharmed Pars moves to Phase 3.
April 21 中国的深圳康泰灭活疫苗进入第三期试验China’s Shenzhen Kangtai moves to Phase 3.
April 20Iran’s Razi Vaccine and Serum Research Institute moves to Phase 2.
April 20E.U. regulators say Johnson & Johnson’s vaccine should carry a warning for possible rare blood clots.
April 16Pfizer says people may need an additional shot of the vaccine within a year.
April 15Denmark stops use of the AstraZeneca vaccine.
April 14The European Commission may not renew its vaccine contracts with AstraZeneca and Johnson & Johnson.
April 13U.S. health agencies call for a pause in Johnson & Johnson vaccinations.
April 12Cuba’s Soberana Plus begins Phase 2.
April 12Massachusetts-based Akston Biosciences enters Phase 1/2.
April 9Turkey’s Koçak Farma begins Phase 1.
April 5The Walter Reed Army Institute of Research enters Phase 1.
April 5Japan’s KM Biologics begins Phase 1/2.
April 2France’s OSE Immunotherapeutics enters Phase 1.

哈萨克斯坦将在7月完成疫苗的三期试验,昨天,4月27日,获得批准使用。

On Monday, Kazakhstan started rolling out its homegrown vaccine, now known as QazVac. ... Instead, it uses an inactivated form of the SARS-CoV-2 virus itself, much like China's CoronaVac and India's Covaxin, which are both in use, and Valneva's vaccine, which isn't there yet.2 days ago

A new vaccine on the scene: Kazakhstan begins rollout of ...


Kazakhstan rolls out its own COVID-19 vaccine​

Reuters

Kazakhstan on Tuesday launched its own, domestically-developed vaccine for mass inoculations against COVID-19, starting with popular locations such as shopping malls.

Almost a million people in the former Soviet republic of 19 million have already received the Russian-developed Sputnik V vaccine that Kazakhstan both imports and produces domestically.

The Central Asian republic's sovereign wealth fund has also ordered a million doses of Chinese-developed Sinopharm vaccine.

But this week, the oil-exporting country made its own vaccine available to the general public, with Healthcare Minister Alexei Tsoi receiving a jab in front of the media.
Like Sputnik V, the QazVac vaccine is delivered in two shots with a three-week interval.
QazVac is currently in a stage 3 trial to be completed by July. All 222 people who participated in the first two stages have developed immunity to COVID-19, with no major side-effects reported, according to its Kazakh developer, the Research Institute for Biological Safety Problems.
In Mega Park, one of the main shopping venues in Almaty, Kazakhstan's biggest city, QazVac was the only available option on Tuesday. Most of the people queuing up for the shot said the brand of vaccine did not matter to them.
"We haven't made it in time for Sputnik (but) I do not think there is any difference between Sputnik and QazVac," said a young woman who only gave her first name, Madina.


"We plan to go to Georgia and we are getting the vaccine so that we do not get sick (with COVID-19) there".

Officials have said domestic development of a vaccine has put Kazakhstan in an elite club of pharmaceutically advanced nations, but acknowledged issues with scaling up production and said they were discussing "bottling" the shot in Turkey.

Kazakhstan has reported over 360,000 COVID-19 cases with 4,381 deaths since the global pandemic began early last year.


PHASE 3

Baylor College of Medicine logo
Texas Children’s Hospital Center for Vaccine Development logo
1619652775636.png
Dynavax logo

After the SARS epidemic in 2002, Baylor College of Medicine researchers began developing a vaccine that could prevent a new outbreak. Despite promising early results, support for the research disappeared. Because the coronaviruses that cause SARS and Covid-19 are very similar, the researchers revived the project in partnership with the Texas Children’s Hospital. The researchers have found that the Covid-19 vaccine produces antibodies in mice.

The Indian company Biological E licensed it in August and launched a Phase 1/2 trial in November, combining the viral proteins with an adjuvant made by Dynavax. On Dec. 29, Biological E and the Coalition for Epidemic Preparedness Innovations announced a partnership to advance the development and manufacturing of the vaccine, with CEPI initially contributing $5 million to the effort.

On April 24, Biological E announced it was starting a Phase 3 trial. Two days later, the Biden administration said it would fund a substantial expansion of Biological E’s manufacturing capability, enabling the company to ramp up to produce at least 1 billion doses of COVID-19 vaccines by the end of 2022.

Updated April 26
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373
辉瑞疫苗递交申请扩大使用范围到2-11岁儿童。

辉瑞申请授权疫苗可以贮存于普通冰箱。

1 hr 15 min ago

Pfizer expects to submit for Covid-19 vaccine emergency authorization for kids ages 2 to 11 in September​

From CNN's Naomi Thomas

Pfizer expects to submit for US Food and Drug Administration emergency use authorization for its Covid-19 vaccine for children ages 2 to 11 in September, the company said during its first quarter earnings teleconference on Tuesday.

The pediatric safety and efficacy study in children ages 6 months to 11 years old is ongoing.

Pfizer CEO Albert Bourla said in prepared remarks, adding that the readout and submission for children 6 months to 2 years is expected in the fourth quarter of 2021.

Phase 2 safety data from Pfizer’s ongoing study in pregnant women is expected by late July or early August, Bourla said.

Bourla also said the company expects to hear back shortly on its application for extended EUA for the vaccine to include 12-to-15-year-olds. On Monday, a federal government official said the FDA is poised to authorize the Pfizer coronavirus vaccine for that age group by early next week.

32 min ago

Pfizer seeking authorization for Covid-19 vaccine to be stored at standard refrigerator temperatures​

From CNN's Virginia Langmaid
Vials of the Pfizer-BioNTech Covid-19 vaccine at Kanto Rosai Hospital in Kanagawa Prefecture, Japan, on March 4.
Vials of the Pfizer-BioNTech Covid-19 vaccine at Kanto Rosai Hospital in Kanagawa Prefecture, Japan, on March 4. Kiyoshi Ota/Bloomberg/Getty Images

Pfizer has submitted information to the US Food and Drug Administration that may allow its Covid-19 vaccine to be stored at standard refrigerator temperatures, the company’s CEO said Tuesday. Such a change could help simplify distribution of the vaccine.

Pfizer CEO Albert Bourla said in an earnings meeting on Tuesday the company submitted new data to the FDA on Friday, and it may “soon” have an emergency use authorization to allow standard refrigeration for up to four weeks.
Currently, Pfizer’s vaccine is authorized to be stored at ultra-cold temperatures, between -80 and -60 degrees Celsius, or in cold storage, between -25 and -15 degrees Celsius, for a maximum of two weeks, which can complicate distribution of the vaccine.

According to Bourla, new data could allow the vaccine to be stored at standard temperatures, between 2 and 8 degrees Celsius, for up to four weeks.

Bourla said Pfizer is working on additional formulations that could further extend the storage time of the vaccine in both standard and ultra-cold refrigerators.
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373
38 min ago

Biden will announce today US will share millions more doses of Covid-19 vaccines globally​

From CNN's Kaitlan Collins

Filled vials wait to be distributed ahead of a Covid-19 vaccine clinic on May 13 in Houston.
Filled vials wait to be distributed ahead of a Covid-19 vaccine clinic on May 13 in Houston. Brandon Bell/Getty Images

In his White House remarks in the next hour, President Biden is set to announce Monday that his administration will share millions more doses of Covid-19 vaccines with other countries in addition to the 60 million doses of the AstraZeneca vaccine he has already committed to sharing by July 4, according to an administration official.

Biden will say the US will share at least 20 million doses of Covid-19 vaccines by the end of next month, totaling 80 million doses that are set to be sent abroad.

Those additional 20 million doses will consist of Moderna, Pfizer and Johnson & Johnson vaccines as well as AstraZeneca, which has to be approved by federal regulators before being shipped overseas. That effort is underway.

Biden will also say White House Covid-19 response coordinator Jeff Zients is in charge of this effort, in coordination with the National Security Council and State Department.

Bloomberg was first to report the news of the additional doses being shared.
 

茶马盐铁

我想看看自定义头衔到底能有多少字。继续加,看系统什么时候把这个字符串截断。呃,居然还有?那就继续吧。
注册
2015-08-14
消息
10,591
荣誉分数
2,720
声望点数
273
38 min ago

Biden will announce today US will share millions more doses of Covid-19 vaccines globally​

From CNN's Kaitlan Collins

Filled vials wait to be distributed ahead of a Covid-19 vaccine clinic on May 13 in Houston.
Filled vials wait to be distributed ahead of a Covid-19 vaccine clinic on May 13 in Houston. Brandon Bell/Getty Images

In his White House remarks in the next hour, President Biden is set to announce Monday that his administration will share millions more doses of Covid-19 vaccines with other countries in addition to the 60 million doses of the AstraZeneca vaccine he has already committed to sharing by July 4, according to an administration official.

Biden will say the US will share at least 20 million doses of Covid-19 vaccines by the end of next month, totaling 80 million doses that are set to be sent abroad.

Those additional 20 million doses will consist of Moderna, Pfizer and Johnson & Johnson vaccines as well as AstraZeneca, which has to be approved by federal regulators before being shipped overseas. That effort is underway.

Biden will also say White House Covid-19 response coordinator Jeff Zients is in charge of this effort, in coordination with the National Security Council and State Department.

Bloomberg was first to report the news of the additional doses being shared.
靠, 这是帝国主义亡我之心不死啊!!
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373

全球领先疫苗,27支疫苗进入3期实验,8支完全批准,7支早期或有限批准。5月18日中国批准深圳康泰灭活疫苗紧急使用。​

1621368724866.png


New additions and recent updates
May 18China authorizes Shenzhen Kangtai’s vaccine for emergency use.
May 14France’s OSE Immunotherapeutics enters Phase 1.
May 10The F.D.A. authorizes the Pfizer-BioNTech vaccine for children 12 to 15.
May 7The W.H.O. gives emergency use authorization to the Sinopharm vaccine.
May 6Russia authorizes a one-dose version of the Gamaleya vaccine, dubbed “Sputnik Light.”
May 5China’s Lanzhou Institute of Biological Products enters Phase 1/2.
May 3Denmark announces it will no longer use Johnson & Johnson’s vaccine.
May 1Baltimore-based Elixirgen Therapeutics enters Phase 1/2.
April 30Turkey’s Scientific and Technological Research Council of Turkey enters Phase 1.
April 28A third vaccine from China’s Sinopharm enters Phase 1/2.
April 28Kazakhstan begins public use of its QazVac vaccine.
April 26A vaccine from Baylor College of Medicine and Texas Children’s Hospital moves to Phase 3.
April 23The European Commission is preparing a legal case against AstraZeneca for failing to deliver enough doses.
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373

全球领先疫苗,27支疫苗进入3期实验,8支完全批准,7支早期或有限批准。5月18日中国批准深圳康泰灭活疫苗紧急使用。​

浏览附件976293

New additions and recent updates
May 18China authorizes Shenzhen Kangtai’s vaccine for emergency use.
May 14France’s OSE Immunotherapeutics enters Phase 1.
May 10The F.D.A. authorizes the Pfizer-BioNTech vaccine for children 12 to 15.
May 7The W.H.O. gives emergency use authorization to the Sinopharm vaccine.
May 6Russia authorizes a one-dose version of the Gamaleya vaccine, dubbed “Sputnik Light.”
May 5China’s Lanzhou Institute of Biological Products enters Phase 1/2.
May 3Denmark announces it will no longer use Johnson & Johnson’s vaccine.
May 1Baltimore-based Elixirgen Therapeutics enters Phase 1/2.
April 30Turkey’s Scientific and Technological Research Council of Turkey enters Phase 1.
April 28A third vaccine from China’s Sinopharm enters Phase 1/2.
April 28Kazakhstan begins public use of its QazVac vaccine.
April 26A vaccine from Baylor College of Medicine and Texas Children’s Hospital moves to Phase 3.
April 23The European Commission is preparing a legal case against AstraZeneca for failing to deliver enough doses.

只是说要做临床试验,但是我找了很久也没有找到报道的实验数据。
而且这个是只有安徽批准使用,跟国内了解了一下,安徽几个城市都用这个,而其他几个省都没有用。
个人觉得疫苗审批应该国家说了算,
今天中国特批了深圳的康泰灭活疫苗,不知道三期数据是不是发表过,别以后又忘了啊。

 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
25,304
荣誉分数
6,297
声望点数
373
Stemirna Therapeutics logo
Shanghai East Hospital logo


Chinese researchers at Stemirna Therapeutics have developed an mRNA vaccine in collaboration with Shanghai East Hospital. They registered a Phase 1 trial on May 1.

中国上海斯微生物与同济大学附属东方医院联合研发的mRNA疫苗5月1日进入1期试验。

关于我们​

斯微生物首次将mRNA药物及高端纳米制剂平台带入中国,并不断探索创新,努力成为亚洲乃至全世界的mRNA药物领导者,为全世界的患者提供更加有效的健康和治疗产品。

我们相信mRNA药物是一个具有巨大潜力的治疗平台,可以为癌症、传染病、罕见病等疾病带来更加快捷和有效的治疗方式。斯微生物的两大核心技术平台是我们后期开发mRNA药物的基础,更是我们全面领先的优势。

斯微生物于2016年在上海张江成立,由美国MD Anderson肿瘤中心的博士团队归国创建,现坐落于上海金桥自由贸易区。

斯微生物于2016年由美国的海归博士团队在上海张江药谷创建, 致力于打造中国领先的mRNA药物平台和产品管线。

2016年5月​

斯微生物在张江成立

2017年7月​

休斯顿卫理会医院授予斯微生物在LPP递送平台的全球独家商业化权益

2017年9月​

获得近2000万天使轮投资

2018年5月​

建成mRNA生产中心并开始产品管线研发

2018年9月​

mRNA合成平台验证、纳米制剂产业化生产验证

2018年11月​

第一位肿瘤患者给药

2019年4月​

获得近亿元A轮投资
 
顶部